Butyric acid enhances in vivo expression of hTNF-alpha in transduced melanoma cell line.
Butyric acid (NaBut) and its derivatives are well-known agents eliciting tumor cell differentiation and apoptosis. In experimental models, NaBut is also used to enhance the efficacy of viral vectors. With the use of B78 murine melanoma cells transduced with the retroviral vector containing human tumor necrosis factor alpha (hTNF-alpha) gene, we investigated the ability of NaBut to increase the cytokine expression. We observed an increase in hTNF-alpha expression in vitro after incubation with NaBut. We also describe that the NaBut pro-drug tributyrin is able to increase hTNF-alpha expression in transduced B78 cells in a tumor vaccination model in mice. This observation strongly suggests a novel potential role for NaBut and its derivatives in tumor therapy. It could be used not only as a therapeutic directly acting on tumor cells but, in parallel, as a genetic vaccine "enhancer".
Giermasz
A
A
Department of Immunology, Centre for Biostructure Research, The Medical University of Warsaw, Poland.
Grzela
T
T
Nowis
D
D
Makowski
M
M
Czajka
A
A
Stoklosa
T
T
Lasek
W
W
Dabrowsk
A
A
Wiznerowicz
M
M
Mackiewicz
A
A
Jakóbisiak
M
M
D000818:Animals; D002087:Butyrates / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D008546:Melanoma, Experimental / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D012190:Retroviridae / Q000235:genetics; D014161:Transduction, Genetic; D014407:Tumor Cells, Cultured; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis* / Q000235:genetics
D002087:Butyrates; D014409:Tumor Necrosis Factor-alpha